Junran Sun

Junran Sun

Auto-generated profile, based on publicly available information

Junran Sun

Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Epidemiology and Health
Verified
Journal Article
Open access
PDF file
XZXiaohuan Zhao
Xiaohuan Zhao
QBQiyu Bo
Qiyu Bo
JSJunran Sun
Junran Sun
JCJieqiong Chen
Jieqiong Chen
TLTong Li
Tong Li
Xiaodong SunXiaodong Sun
Xiaodong Sun
OBJECTIVES: This study evaluated the association between obesity and glaucoma in middle-aged and older people. A population-based retrospective cohort study was conducted using data from the China Health and Retirement Longitudinal Study.METHODS: Glaucoma was assessed via self-reports. Multivariate logistic regression analysis and a Cox proportional hazards model were used to assess the relationship between obesity and glaucoma risk.RESULTS: Older males living in urban areas who were single, smokers, and non-drinkers were found to have a significantly higher incidence of glaucoma (all p<0.05). Diabetes, hypertension, and kidney disease were also associated with higher glaucoma risk, while dyslipidemia was associated with lower risk (all p<0.05). After the model was adjusted for demographic, socioeconomic, and health-related variables, obesity was significantly associated with a 10.2% decrease in glaucoma risk according to the Cox proportional hazards model (hazard ratio, 0.90; 95% confidence interval [CI], 0.83 to 0.97) and an 11.8% risk reduction in the multivariate logistic regression analysis (odds ratio, 0.88; 95% CI, 0.80 to 0.97). A further subgroup analysis showed that obesity was associated with a reduced risk of glaucoma in people living in rural areas, in smokers, and in those with kidney disease (all p<0.05). Obesity also reduced glaucoma risk in people with diabetes, hypertension, or dyslipidemia more than in healthy controls (all p<0.05).CONCLUSIONS: This cohort study suggests that obesity was associated with a reduced risk of glaucoma, especially in rural residents, smokers, and people with kidney disease. Obesity exerted a stronger protective effect in people with diabetes, hypertension, or dyslipidemia than in healthy people.

19 November 2025 in American Journal of Ophthalmology
Verified
Journal Article
Open access
YHYu Hong
Yu Hong
JLJianqing Li
Jianqing Li
ZCZhixuan Chen
Zhixuan Chen
TZTing Zhang
Ting Zhang
MCMinghao Chen
Minghao Chen
Xiaodong SunXiaodong Sun
Xiaodong Sun
To delineate the intricate interplay between inflammation, retinal remodeling, and genotype in CRB1-associated inherited retinal diseases (CRB1-IRDs). Retrospective, multicenter observational case series. We evaluated 66 CRB1-retinopathy patients from 61 unrelated families recruited from 4 tertiary hospitals in China between June 2016 and July 2024. Comprehensive medical records, ophthalmic examination and multimodal fundus imaging were obtained and reviewed. The main outcome measures included: inflammatory-like fundus characteristics, quantitative assessments of retinal thickness, and genotype-phenotype correlations regarding both inflammatory-like features and the severity of outer retinal disruption. Among 66 patients (59.1% male, aged 3-57 years), clinical diagnoses included retinitis pigmentosa (RP, 60.6%), Leber congenital amaurosis (LCA, 33.3%), and cone-rod dystrophy (6.1%). Several inflammatory-like fundus features were identified, including preserved para-arteriolar retinal pigment epithelium (PPRPE, 77.5%), yellow-white lesions (68.1%), vascular sheathing (48.9%), nummular pigmentation (26.6%) and Coats-like vasculopathy (3.2%). In CRB1-IRD retinas with residual outer nuclear layer (ONL), inner nuclear layer thickening was observed, whereas those with complete ONL loss exhibited progressive atrophy. Patients with biallelic loss-of-function variants exhibited significantly higher prevalence of PPRPE (88% vs 64.7%, P = .042), yellow-white lesions (80% vs 52.9%, P = .038), and greater outer retinal disruption compared to those with biallelic non-null mutations (outer plexiform layer continuity: 18.2% vs 50%, P = .014; ellipsoid zone retention: 13.6% vs 40%, P = .031). This study identifies retinal inflammation-like changes as core features of CRB1-IRD, might associated with retinal remodeling and genotype. These findings provide new insights into CRB1-IRD and establish references for diagnosis and future clinical trial design.

5 January 2026 in BMJ Open Ophthalmology
Verified
Journal Article
Open access
ZWZilin Wang
Zilin Wang
JSJunran Sun
Junran Sun
KLKun Liu
Kun Liu
LTLiming Tao
Liming Tao
QLQinghuai Liu
Qinghuai Liu
Xiaodong SunXiaodong Sun
Xiaodong Sun
Objective: To evaluate the safety, tolerability and preliminary efficacy of IBI324, a vascular endothelial growth factor-A/angiopoietin-2 bispecific antibody, in participants with diabetic macular oedema (DME). Methods and analysis: This multicentre, open-label, phase 1 dose-escalation clinical trial consisted of a single ascending dose (SAD) stage and a multiple ascending dose (MAD) stage. 24 participants with fovea-involving DME were enrolled. SAD participants received a single intravitreal injection (IVT) of 0.5 mg, 2 mg or 4 mg IBI324 and were followed up until Day 42 post injection. In the MAD stage, six participants each received 3 monthly IVTs of 2 mg or 4 mg IBI324 and were followed up until determined as ‘treatment needed’ per prespecified criteria or until 24 weeks after first dose. The primary endpoints were incidence of dose-limiting toxicities (DLTs), adverse events (AEs) and changes in vital signs and laboratory test findings. Results: No DLT, treatment-related AE, AE of special interest or ocular serious AE was reported. Treatment-emergent adverse events (TEAEs), all mild or moderate in severity, were observed in 4 (33.3%) SAD participants and 11 (91.7%) MAD participants. TEAEs of the study eye included intraocular pressure increased, conjunctival haemorrhage, allergic conjunctivitis, posterior capsular opacification and visual acuity decreased. Mean best-corrected visual acuity increase and mean central subfield thickness decrease from baseline in the study eye were observed in all dose groups, accompanied by intraretinal fluid/subretinal fluid improvements. 16 weeks after the last dose, 7 (58.3%) MAD 2 mg and 6 (50.0%) MAD 4 mg participants remained free of ‘treatment needed’. Conclusion: IBI324 was well tolerated with evidence of functional and anatomical improvement in patients with DME. Trial registration number: NCT05489718 .